Ionis Pharmaceuticals in the NEWS
Yesterday, July 22, 2024, Ionis Pharmaceuticals (IONS) announced positive results from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman . . .
This content is for paid subscribers.
Impacting News
July 23, 2024
